OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Decrease in Short Interest

OptimizeRx Corp. (NASDAQ:OPRX) was the target of a large drop in short interest in June. As of June 30th, there was short interest totaling 1,129,328 shares, a drop of 39.0% from the June 15th total of 1,851,668 shares. Currently, 6.5% of the company’s stock are sold short. Based on an average daily volume of 624,522 shares, the days-to-cover ratio is currently 1.8 days.

Wall Street Analysts Forecast Growth

OPRX has been the topic of several analyst reports. B. Riley Financial lowered their target price on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Stephens reduced their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Weiss Ratings downgraded OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, May 14th. Finally, Lake Street Capital reduced their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $13.43.

Institutional Trading of OptimizeRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPRX. Quantbot Technologies LP bought a new position in OptimizeRx in the 2nd quarter worth approximately $44,000. BNP Paribas Financial Markets raised its position in shares of OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of OptimizeRx in the fourth quarter valued at about $62,000. Aaron Wealth Advisors LLC bought a new stake in shares of OptimizeRx in the first quarter valued at about $66,000. Finally, Hsbc Holdings PLC acquired a new stake in OptimizeRx during the first quarter worth about $85,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Stock Performance

OPRX traded up $0.04 during trading on Friday, hitting $6.69. The stock had a trading volume of 272,719 shares, compared to its average volume of 450,914. The firm has a market cap of $125.50 million, a PE ratio of 19.11 and a beta of 1.08. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $22.25. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. The company has a 50 day simple moving average of $5.46 and a 200-day simple moving average of $7.54.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. Analysts expect that OptimizeRx will post 0.51 EPS for the current year.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.